Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

Andrea Casadei Gardini, Emanuela Scarpi, Luca Faloppi, Mario Scartozzi, Nicola Silvestris, Daniele Santini, Giorgio de Stefano, Giorgia Marisi, Francesca V. Negri, Francesco Giuseppe Foschi, Martina Valgiusti, Giorgio Ercolani, Giovanni Luca Frassineti

Research output: Contribution to journalArticlepeer-review

Abstract

We evalueted a systemic immune-inflammation index (SII), neutrophil-tolymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.

Original languageEnglish
Pages (from-to)67142-67149
Number of pages8
JournalOncotarget
Volume7
Issue number41
DOIs
Publication statusPublished - 2016

Keywords

  • Biomarker
  • Hepatocellular carcinoma
  • Inflammation
  • Neutrophil-to-lymphocyte ratio
  • Systemic immune-inflammation index

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib'. Together they form a unique fingerprint.

Cite this